1446021-66-4 Usage
General Description
(3aR,5S,6aS)-tert-butyl 5-(methylamino)hexahydrocyclopenta[c]pyrrole-2(1H)-carboxylate is a chemical compound with a molecular formula of C14H25NO2. It is a derivative of cyclopenta[c]pyrrole, which has potential pharmaceutical and medicinal applications. The tert-butyl group is a common protective group used in organic synthesis to prevent unwanted reactions or to enhance the properties of the molecule, while the methylamino group can be found in various pharmaceuticals and biologically active compounds. (3aR,5S,6aS)-tert-butyl 5-(methylamino)hexahydrocyclopenta[c]pyrrole-2(1H)-carboxylate is an ester, which means it can be hydrolyzed to release the corresponding carboxylic acid and alcohol. The presence of a carboxylic acid group and an amino group make this compound a potential candidate for drug development or medicinal chemistry applications.
Check Digit Verification of cas no
The CAS Registry Mumber 1446021-66-4 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,4,4,6,0,2 and 1 respectively; the second part has 2 digits, 6 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 1446021-66:
(9*1)+(8*4)+(7*4)+(6*6)+(5*0)+(4*2)+(3*1)+(2*6)+(1*6)=134
134 % 10 = 4
So 1446021-66-4 is a valid CAS Registry Number.
1446021-66-4Relevant articles and documents
JAK KINASE INHIBITOR, PREPARATION METHOD FOR SAME, AND APPLICATIONS THEREOF IN FIELD OF MEDICINE
-
, (2022/01/24)
-
Substituted heteroaryl compound and composition and application thereof
-
, (2016/10/10)
The invention provides a substituted heteroaryl compound, a composition thereof and application of the substituted heteroaryl compound and the composition. The compound is a compound shown in a formula (I) or a stereisomer, or a tautomer, or nitric oxide, or solvate, or a metabolite, or a pharmaceutically acceptable salt or a prodrug of the compound shown in the formula (I). The invention further provides the drug composition containing the compound, and the compound and the drug composition can adjust activity of JAK kinase and are used for preventing, handling, treating, and relieving diseases or disorder mediated by the JAK kinase.
SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE
-
, (2015/07/07)
The present invention provides new heteroaryl compounds, pharmaceutical acceptable salts and formulations thereof useful in preventing, treating or lessening the severity of JAK-mediated diseases. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of JAK-mediated diseases.
